Everolimus

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 373-392

  Hasskarl, Jens ^a  

^a Department Innere Medizin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIFUNGAL AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CYCLOSPORIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROMYCIN; EVEROLIMUS; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; NAVELBINE; OCTREOTIDE; PACLITAXEL; PLACEBO; PYRROLE DERIVATIVE; RIFAMPICIN; RITUXIMAB; SUNITINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BILIARY TRACT CANCER; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RISK; CANCER SURVIVAL; CARCINOID; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; ENDOMETRIUM CANCER; EPSTEIN BARR VIRUS INFECTION; ESOPHAGUS CANCER; GERM CELL TUMOR; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFECTION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LIVER CANCER; LIVER CELL CARCINOMA; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MONOTHERAPY; NEUROENDOCRINE TUMOR; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SARCOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; TRANSITIONAL CELL CARCINOMA; TUBEROUS SCLEROSIS; UTERINE CERVIX CANCER; ANIMAL; DRUG EFFECT; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84906839292     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_23     Document Type: Article

References (69)

1. Andre F et al (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol: Official J Am Soc Clin Oncol 28(34): 5110-5115.
2. Awada A et al (2008) The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 44(1): 84-91.
3. Barnes JA et al (2013) Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 98(4): 615-619.
4. Baselga J et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol: Official J Am Soc Clin Oncol 27(16): 2630-2637.
5. Baselga J et al (2012a) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Eng J Med 366(6): 520-529.
6. Baselga J et al (2012b) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Eng J Med 366(2): 109-119.
7. Bissler JJ et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381(9869): 817-824.
8. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4(5): 335-348.
9. Boulay A et al (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clinical Cancer Res: Official J Am Assoc Cancer Res 11(14): 5319-5328.
10. Brown EJ et al (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369(6483): 756-758.
11. Carracedo A et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Investig 118(9): 3065-3074.
12. Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91(8): 1420-1424.
13. Crazzolara R et al (2009) Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 113(14): 3297-3306.
14. Doi T et al (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol: Official J Am Soc Clin Oncol 28(11): 1904-1910.
15. Ehninger D et al (2008) Reversal of learning deficits in a Tsc2± mouse model of tuberous sclerosis. Nat Med 14(8): 843-848.
16. Eng CP et al (1991) Inhibition of skin graft rejection in mice by rapamycin: a novel immunosuppressive macrolide. Transpl Proc 23(1 Pt 1): 868-869.
17. Franz DN et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861): 125-132.
18. Geoerger B et al (2001) Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61(4): 1527-1532.
19. Hainsworth JD et al (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol: Official J Am Soc Clin Oncol 28(13): 2131-2136.
20. Haritunians T et al (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21(2): 333-339.
21. Houghton PJ (2010) Everolimus. Clinical cancer research: an official journal of the American Association for Cancer Research 16(5): 1368-1372.
22. Huynh H et al (2009) RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 13(7): 1371-1380.
23. Jacinto E et al (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6(11): 1122-1128.
24. Jerusalem G et al (2011) Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 125(2): 447-455.
25. Johnston PB et al (2010) A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 85(5): 320-324.
26. Krueger DA et al (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Eng J Med 363(19): 1801-1811.
27. Lane HA et al (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res: Official J Am Assoc Cancer Res 15(5): 1612-1622.
28. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2): 274-293.
29. Levine AJ et al (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20(3): 267-275.
30. Lu CH et al (2007) Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res: Official J Am Assoc Cancer Res 13(19): 5883-5888.
31. Majumder PK et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10(6): 594-601.
32. Mak BC, Yeung RS (2004) The tuberous sclerosis complex genes in tumor development. Cancer Invest 22(4): 588-603.
33. Manning BD, Cantley LC (2003) United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 31(Pt 3): 573-578.
34. Meikle L et al (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci: Official J Soc Neurosc 28(21): 5422-5432.
35. Mita M et al (2008) Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 17(12): 1947-1954.
36. Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637): 449-456.
37. Motzer RJ et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18): 4256-4265.
38. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Pittman KB, Sabbatini R, Rha SY, Flaig TW et al (2012) Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 31(15_suppl): 4504.
39. Nagata Y et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2): 117-127.
40. Nishioka C et al (2008) Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 22(12): 2159-2168.
41. O'Connor OA et al (2010) PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib. ASH Annu Meet Abstr 116(21): 3963.
42. O'Donnell A et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol: Official J Am Soc Clin Oncol 26(10): 1588-1595.
43. O'Reilly T, McSheehy PM (2010) Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 3(2): 65-79.
44. O'Reilly T et al (2010) Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol 65(4): 625-639.
45. O'Regan R, Ozguroglu M, Andre F, Toi M, Jerusalem GHM, Wilks S, Isaacs C, Xu B, Masuda N, Arena FP et al (2013) Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). ASCO Meeting Abstracts 31(15_suppl): 505.
46. Orlova KA, Crino PB (2010) The tuberous sclerosis complex. Ann N Y Acad Sci 1184: 87-105.
47. Pavel ME et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808): 2005-2012.
48. Podsypanina K et al (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten± mice. Proc Natl Acad Sci USA 98(18): 10320-10325.
49. Renner C et al (2012) A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 97(7): 1085-1091.
50. Sabatini DM et al (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycindependent fashion and is homologous to yeast TORs. Cell 78(1): 35-43.
51. Saunders P et al (2011) The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica 96(1): 69-77.
52. Schuler W et al (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64(1): 36-42.
53. Sehgal SN (1995) Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 17(6): 660-665.
54. Sehgal SN, Baker H, Vezina C (1975) Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 28(10): 727-732.
55. Singh JC, Stein S, Volm M, Smith JA, Novik Y, Speyer JL, Meyers M, Adams S, Omene CO, Muggia F et al (2012) Phase II trial of RAD001 plus carboplatin in patients with triplenegative metastatic breast cancer. ASCO Meeting Abstracts 30(15_suppl): e11529.
56. Swain SM et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6): 461-471.
57. Taguchi F et al (2011) Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs 29(6): 1198-1205.
58. Verma S et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Eng J Med 367(19): 1783-1791.
59. Villanueva A et al (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135(6): 1972-1983 (e1-11).
60. Wang M et al (2012) Pillar-1: multicenter phase 2 study of everolimus for patients with mantle cell lymphoma who are refractory or intolerant to bortezomib. ASH Annu Meet Abstr 120(21): 2751.
61. Wanner K et al (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134(5): 475-484.
62. Witzig TE et al (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25(2): 341-347.
63. Wong M (2012) mTOR as a potential treatment target for epilepsy. Future Neurol 7(5): 537-545.
64. Xu ZZ et al (2010) Combination of rituximab and the mTOR inhibitor everolimus (RAD001) in diffuse large B cell lymphoma. Leuk Lymphoma 85(5): 320-324.
65. Yao JC et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol: Official J Am Soc Clin Oncol 26(26): 4311-4318.
66. Yao JC et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol: Official J Am Soc Clin Oncol 28(1): 69-76.
67. Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Eng J Med 364(6): 514-523.
68. Yoon DH et al (2012) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106(6): 1039-1044.
69. Zhu AX et al (2011) Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117(22): 5094-5102.